RBC Capital analyst Brian Abrahams maintained a Buy rating on Constellation Pharmaceuticals (CNST) today and set a price target of $52.00. The company’s shares closed last Friday at $21.00, close to its 52-week low of $17.00.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.8% and a 50.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Constellation Pharmaceuticals with a $37.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.49 and a one-year low of $17.00. Currently, Constellation Pharmaceuticals has an average volume of 545.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.
